US Pharma MarketingThe post Takeda’s Phase II/III trial of TAK-881 meets primary endpoint appeared first on Clinical Trials Arena.
Takeda’s Phase II/III trial of TAK-881 meets primary endpoint
Takeda’s TAK-881-3001 pivotal Phase II/III clinical trial of TAK-881 in patients with PID has met its primary endpoint. The data showed that TAK-881 provided immune protection comparable to Hyqvia. The trial assessed TAK-881 in adults and children with PID. Credit: Saiful52 / Shutterstock.com. Takeda’s TAK-881-3001 pivotal Phase II/III clinical trial of TAK-881 in patients with primary immunodeficiency disease (PID) has met its primary endpoint. The study demonstrated pharmacokinetic comparability between TAK-881, an Immune Globulin Subcutaneous (Human) 20% Solution with Recombinant Human Hyaluronidase, and Hyqvia. LOA and PTSR Model - TAK-102 in Hepatocellular Carcinoma Reports LOA and PTSR Model - TAK-500…
Takeda’s TAK-881-3001 pivotal Phase II/III clinical trial of TAK-881 in patients with PID has met its primary endpoint.
Source: Clinical Trials Arena